Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · LALPATHLAB

LALPATHLAB

HealthcareHealthcare Services₹32863 cr market cap
₹1968.50 ▲ +0.16% today As of 19 Nov 2026
52-week low ₹1307.6052-week high ₹2029.40

-3.2% from the 52-week high · +50.3% above the low

Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,048 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.

The short version. LALPATHLAB reported revenue of ₹874 crore for Sep 2026, up 19.6% from a year earlier. Net profit was ₹192 crore (up 27.2% year on year). Return on equity was 20.1% in Mar 2026. Promoter holding was 52.93% in Sep 2026, down 0.98 points over 8 quarters.

1 · The price

How has the stock traded?

LALPATHLAB trades 3.2% below its 52-week high and 50.3% above its 52-week low.

Change over period: —

1M+6.6%
3M+4.1%
6M+17.8%
1Y+23.5%

2 · The business

Is it growing?

Sales, year on year+19.6%

Sep 2026 revenue of ₹874 cr.

Profit, year on year+27.2%

Sep 2026 net profit of ₹192 cr.

Net margin22.0%

1.4 pts higher than a year earlier.

3-year growth28.3% profit

Revenue compounded at 11.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue874798703660731670603597
Net profit1921701319015113215597
Net margin %22.021.218.713.720.619.825.716.2
EPS (₹)11.4510.117.845.48.997.99.265.78

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue27632461222720172087158113301203
Net profit505487358239345292226199
Net margin %18.319.816.111.816.518.417.016.6
EPS (₹)30.1329.1421.4214.3320.6917.4913.5511.95

3 · The quality

How well does it turn capital into profit?

Return on equity was 20.1% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %20.122.419.314.3
Return on capital %25.728.026.919.9
EBITDA margin %29.830.929.525.8
Net margin %17.619.115.611.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.6%11.9%
Profit CAGR28.3%11.6%
Debt to equity0.00
Interest cover30.4x
Current ratio3.48
P/E ratio56.7

4 · The owners

Who holds it, and are they adding?

Promoter holding52.93%

Down 0.98 pts over 8 quarters.

Foreign institutions18.73%

Down 8.09 pts over 8 quarters.

Domestic institutions21.58%

Up 8.41 pts over 8 quarters.

Mutual fund schemes169

+50 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter53.9153.9153.7953.2153.2153.2153.1952.93-0.98
FII26.8223.9121.6821.8620.2917.1817.3618.73-8.09
DII13.1716.0817.9118.4919.2121.3821.5921.58+8.41
Public5.825.846.236.076.947.877.476.35+0.53

Mutual fund holdings · Oct 2026

169 schemes hold this stock

119 the month before.

  • ICICI Prudential Life Cycle Fund 20318.06% of NAV
  • PGIM INDIA HEALTHCARE FUND4.34% of NAV
  • NJ ELSS Tax Saver Fund4.11% of NAV
  • NJ Flexi Cap Fund4.09% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND3.9% of NAV
  • Capitalmind Flexi Cap Fund3.15% of NAV
  • DSP Nifty Smallcap250 Quality 50 Index Fund3.14% of NAV
  • the Quantum Ethical Fund3.14% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for LALPATHLAB are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about LALPATHLAB

What is the LALPATHLAB share price?

LALPATHLAB (LALPATHLAB) last closed at ₹1,968.50, up 0.16% on the day. Its 52-week range is ₹1,307.60 to ₹2,029.40.

What is the market cap of LALPATHLAB?

LALPATHLAB has a market capitalisation of about ₹32,863 crore. Its price-to-earnings ratio is 56.7.

How are LALPATHLAB's latest results?

LALPATHLAB reported revenue of ₹874 crore for Sep 2026, up 19.6% from a year earlier. Net profit was ₹192 crore (up 27.2% year on year). Return on equity was 20.1% in Mar 2026. Promoter holding was 52.93% in Sep 2026, down 0.98 points over 8 quarters.

Who owns LALPATHLAB?

As of Sep 2026, shareholding was: Promoter 52.93%, FII 18.73%, DII 21.58%, Public 6.35%.

How many mutual funds hold LALPATHLAB?

169 mutual fund schemes held LALPATHLAB in October 2026. That compares with 119 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jun 2026 · Final Dividend - Rs. 4
  • 05 Feb 2026 · Interim Dividend - Rs. 3.5
  • 19 Dec 2025 · Bonus issue 1:1
  • 07 Nov 2025 · Interim Dividend - Rs. 7
  • 06 Aug 2025 · Interim Dividend - Rs. 6
  • 06 Jun 2025 · Final Dividend - Rs. 6

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.